314 related articles for article (PubMed ID: 21504942)
1. Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target.
Shiota M; Yokomizo A; Naito S
J Mol Endocrinol; 2011 Aug; 47(1):R25-41. PubMed ID: 21504942
[TBL] [Abstract][Full Text] [Related]
2. Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression.
Shiota M; Takeuchi A; Song Y; Yokomizo A; Kashiwagi E; Uchiumi T; Kuroiwa K; Tatsugami K; Fujimoto N; Oda Y; Naito S
Endocr Relat Cancer; 2011 Aug; 18(4):505-17. PubMed ID: 21652770
[TBL] [Abstract][Full Text] [Related]
3. Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer.
Shiota M; Yokomizo A; Naito S
Free Radic Biol Med; 2011 Oct; 51(7):1320-8. PubMed ID: 21820046
[TBL] [Abstract][Full Text] [Related]
4. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
Vis AN; Schröder FH
BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
[TBL] [Abstract][Full Text] [Related]
5. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.
Kawata H; Arai S; Nakagawa T; Ishikura N; Nishimoto A; Yoshino H; Shiraishi T; Tachibana K; Nakamura R; Sato H
Prostate; 2011 Sep; 71(12):1344-56. PubMed ID: 21308717
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
Zaia A; Fraizer GC; Piantanelli L; Saunders GF
Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720
[TBL] [Abstract][Full Text] [Related]
7. Human heterochromatin protein 1 isoform HP1beta enhances androgen receptor activity and is implicated in prostate cancer growth.
Shiota M; Song Y; Yokomizo A; Tada Y; Kuroiwa K; Eto M; Oda Y; Inokuchi J; Uchiumi T; Fujimoto N; Seki N; Naito S
Endocr Relat Cancer; 2010 Jun; 17(2):455-67. PubMed ID: 20308360
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor (AR) aberrations in castration-resistant prostate cancer.
Waltering KK; Urbanucci A; Visakorpi T
Mol Cell Endocrinol; 2012 Sep; 360(1-2):38-43. PubMed ID: 22245783
[TBL] [Abstract][Full Text] [Related]
9. Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model.
Terada N; Shimizu Y; Kamba T; Inoue T; Maeno A; Kobayashi T; Nakamura E; Kamoto T; Kanaji T; Maruyama T; Mikami Y; Toda Y; Matsuoka T; Okuno Y; Tsujimoto G; Narumiya S; Ogawa O
Cancer Res; 2010 Feb; 70(4):1606-15. PubMed ID: 20145136
[TBL] [Abstract][Full Text] [Related]
10. Peroxiredoxin 2 in the nucleus and cytoplasm distinctly regulates androgen receptor activity in prostate cancer cells.
Shiota M; Yokomizo A; Kashiwagi E; Takeuchi A; Fujimoto N; Uchiumi T; Naito S
Free Radic Biol Med; 2011 Jul; 51(1):78-87. PubMed ID: 21539911
[TBL] [Abstract][Full Text] [Related]
11. Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.
Thelen P; Heinrich E; Bremmer F; Trojan L; Strauss A
Prostate; 2013 Nov; 73(15):1699-709. PubMed ID: 23868789
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer.
Koivisto P; Kononen J; Palmberg C; Tammela T; Hyytinen E; Isola J; Trapman J; Cleutjens K; Noordzij A; Visakorpi T; Kallioniemi OP
Cancer Res; 1997 Jan; 57(2):314-9. PubMed ID: 9000575
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer.
Urbanucci A; Sahu B; Seppälä J; Larjo A; Latonen LM; Waltering KK; Tammela TL; Vessella RL; Lähdesmäki H; Jänne OA; Visakorpi T
Oncogene; 2012 Apr; 31(17):2153-63. PubMed ID: 21909140
[TBL] [Abstract][Full Text] [Related]
15. Regulation of FGF8 expression by the androgen receptor in human prostate cancer.
Gnanapragasam VJ; Robson CN; Neal DE; Leung HY
Oncogene; 2002 Aug; 21(33):5069-80. PubMed ID: 12140757
[TBL] [Abstract][Full Text] [Related]
16. Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer.
Davis JN; Wojno KJ; Daignault S; Hofer MD; Kuefer R; Rubin MA; Day ML
Cancer Res; 2006 Dec; 66(24):11897-906. PubMed ID: 17178887
[TBL] [Abstract][Full Text] [Related]
17. Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression.
Shiota M; Yokomizo A; Tada Y; Inokuchi J; Kashiwagi E; Masubuchi D; Eto M; Uchiumi T; Naito S
Oncogene; 2010 Jan; 29(2):237-50. PubMed ID: 19802001
[TBL] [Abstract][Full Text] [Related]
18. Regulation of androgen receptor levels: implications for prostate cancer progression and therapy.
Burnstein KL
J Cell Biochem; 2005 Jul; 95(4):657-69. PubMed ID: 15861399
[TBL] [Abstract][Full Text] [Related]
19. Genomic strategy for targeting therapy in castration-resistant prostate cancer.
Mendiratta P; Mostaghel E; Guinney J; Tewari AK; Porrello A; Barry WT; Nelson PS; Febbo PG
J Clin Oncol; 2009 Apr; 27(12):2022-9. PubMed ID: 19289629
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor amplification is reflected in the transcriptional responses of Vertebral-Cancer of the Prostate cells.
Makkonen H; Kauhanen M; Jääskeläinen T; Palvimo JJ
Mol Cell Endocrinol; 2011 Jan; 331(1):57-65. PubMed ID: 20728506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
